Understanding Competition in U.S. Prescription Drug Markets: Entry and Supply Chain Dynamics #00490

Submission Number:
00490
Commenter:
Abraham Funk
State:
Missouri
Initiative Name:
Understanding Competition in U.S. Prescription Drug Markets: Entry and Supply Chain Dynamics
Please consider at a minimum studying the effect PBMs reimbursement methods have a negative impact on consumer and government cost savings. Out of Pocket costs for consumers are higher due to post adjudication application of DIR fees. This costs the government money and pads the pockets of multi-billion dollar companies. I understand they state they operate on thin % margins. But it doesn't take many percentage points of a billion dollars to make a lot of money. This practice is harmful to patients financially and I believe clinically as more and more are driven from local clinically trained pharmacists that see them face to face to distant mail order companies with no true patient connection. As an owner of a small family owned pharmacy I see this effect on my patients daily. They struggle to make ends meet and sometimes have to choose medicine or food while large companies have the audacity to charge the patient more so they can make an extra dollar. It may be legal, it just doesn't seem right. There are times I even choose to pay for a patient's medication out of my pocket so they get what they need. I have never seen a PBM d that. I am sure they have the money to hire fancy lawyers and lobbyists to plead their case. But listen to the individual people who don't have that ability and you will find a very different picture than the one they paint. Thank you for considering this request.